Sector News

What Biogen wants in a new CIO

July 18, 2016
Life sciences

Adriana Karaboutis, executive vice president of technology, business solutions and corporate affairs at Biogen Inc., is on the hunt for a new CIO.

The biopharmaceutical company, like many companies, uses technology not only as a means to make operations more efficient but also as a base for new products and a way to find new customers. Ms. Karaboutis, a former CIO herself at Dell Inc. from 2011 to 2014, has clear ideas about what she does and does not want in a new information chief. Financial acumen ranks high on her list.

“Every leader, including the leader of technology, should understand the economics and cash flow and balance sheets of the company,” Ms. Karaboutis tells CIO Journal. “You can’t generate revenue if you don’t understand those things. Traditionally, CIOs have taken a flyer on that.”

Matt Griffiths, former CIO at Biogen, left in May after just over a year in the position. The company declined to talk about it and Mr. Griffiths did not respond to a message asking for comment.

In filling the position, Ms. Karaboutis seeks an executive with proven “disruption” experience, she said. That is, someone who can come up with new business processes based on new technology. The CIO role generally has progressed from a manager who oversees the automation of business processes to one who brings new business ideas to C-level peers, she said. The best candidates have done that at other firms, she said, and will be able to do it quickly at Biogen. The company is looking to speed up drug development, for example. For an IT project “that a few years back would take two years, I’m looking at six to eight months and 90-day deliverables within that,” she said. “It’s a much tighter cycle.”

CIOs have gained stature in a digital economy, working closely with chief executives on corporate strategy. “I view technology today very differently than I did five or 10 years ago. It’s no longer a backroom function,” as Target Corp. CEO Brian Cornell recently told CIO Journal.

Biogen’s next CIO must bring fresh thinking about emerging technologies. Biogen has worked with Alphabet Inc.’s Google on using wearable computing devices in testing treatments for multiple sclerosis and Ms. Karaboutis is interested in how to use blockchain online ledgers to streamline and secure supply chain systems. A worthy IT leader, she said, would not wait for another executive to broach such ideas. “The CIO role has become much more peer-to-peer than it was. It’s about saying, ‘Here’s what we should be doing.’”

Ms. Karaboutis has not set a deadline for hiring a new CIO.

By Kim S. Nash

Source: Wall Street Journal

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach